Among the approved treatments for MDS, attention has focused on hypomethylating agents such as 5-azacytidine and decitabine, which are believed to act by inducing the degradation of DNA methyltransferase 1 (DNMT1), leading to the demethylation of CpG islands and the enhanced expression of genes required for normal myeloid hematopoiesis [2]. This evidence concerns the gene DNMT1 and myelodysplastic syndrome.